Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

6 Months Ended

Jan. 31, 2019

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended January 31, 2019	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	12,000		$	7,327			—			—		$	19,327

Operating costs and expenses:
Cost of revenues		11,025			3,723			—			—			14,748
Research and development		—			611		$	222			—			833
Selling, general and administrative		6,200			2,981			—		$	2,316			11,497
Legal fee expense		38			1			—			1,103			1,142
Total operating costs and expenses		17,263			7,316			222			3,419			28,220

Operating income (loss)		(5,263	)		11			(222	)		(3,419	)		(8,893	)

Other income (expense):
Interest		(15	)		14			—			228			227
Other		(29	)		(4	)		—			165			132
Foreign exchange loss		—			126			—			—			126
(Loss) income before income taxes	$	(5,307	)	$	147		$	(222	)	$	(3,026	)	$	(8,408	)

Depreciation and amortization included above	$	374		$	343		$	—		$	51		$	768

Share-based compensation included in above:
Selling, general and administrative	$	40		$	26		$	—		$	225		$	291
Total	$	40		$	26		$	—		$	225		$	291

Capital expenditures	$	409		$	26		$	—		$	6,147		$	6,582

Three months ended January 31, 2018	Clinical Services			Products		Therapeutics			Other			Consolidated
Revenues	$	18,730		$	7,422		—			—		$	26,152

Operating costs and expenses:
Cost of revenues		11,730			3,877		—			—			15,607
Research and development		—			591	$	221			—			812
Selling, general and administrative		6,107			2,878		—		$	2,064			11,049
Legal fee expense		8			25		—			1,667			1,700
Total operating costs and expenses		17,845			7,371		221			3,731			29,168

Operating income (loss)		885			51		(221	)		(3,731	)		(3,016	)

Other income (expense):
Interest		(23	)		11		—			197			185
Other		3			1		—			29			33
Foreign exchange loss		—			800		—			—			800
Income (loss) before income taxes	$	865		$	863	$	(221	)	$	(3,505	)	$	(1,998	)

Depreciation and amortization included above	$	413		$	355	$	—		$	18		$	786

Share-based compensation included in above:
Selling, general and administrative		28		$	21		—		$	159			208
Total	$	28		$	21	$	—		$	159		$	208

Capital expenditures	$	576		$	28	$	—		$	—		$	604

Six months ended January 31, 2019	Clinical Services			Products			Therapeutics			Other			Consolidated
Revenues	$	26,297		$	14,290			—			—		$	40,587

Operating costs and expenses:
Cost of revenues		21,993			6,994			—			—			28,987
Research and development		—			1,118		$	443			—			1,561
Selling, general and administrative		12,260			5,905			—		$	4,302			22,467
Legal fee expense		74			8			—			2,361			2,443
Total operating costs and expenses		34,327			14,025			443			6,663			55,458

Operating income (loss)		(8,030	)		265			(443	)		(6,663	)		(14,871	)

Other income (expense):
Interest		(33	)		30			—			504			501
Other		11			—			—			168			179
Foreign exchange loss (gain)		—			(198	)		—			—			(198	)
(Loss) income before income taxes	$	(8,052	)	$	97		$	(443	)	$	(5,991	)	$	(14,389	)

Depreciation and amortization included above	$	777		$	685		$	—		$	72		$	1,534

Share-based compensation included in above:
Selling, general and administrative		78		$	50			—		$	398			526
Total	$	78		$	50		$	—		$	398		$	526

Capital expenditures	$	763		$	78		$	—		$	6,147		$	6,988

Six months ended January 31, 2018	Clinical Services			Products		Therapeutics			Other			Consolidated
Revenues	$	38,264		$	14,764		—			—		$	53,028

Operating costs and expenses:
Cost of revenues		23,772			7,266		—			—			31,038
Research and development		—			1,114	$	445			—			1,559
Selling, general and administrative		12,202			5,506		—		$	4,246			21,954
Legal fee expense		21			28		—			2,082			2,131
Total operating costs and expenses		35,995			13,914		445			6,328			56,682

Operating income (loss)		2,269			850		(445	)		(6,328	)		(3,654	)

Other income (expense):
Interest		(48	)		23		—			367			342
Other		17			8		—			44			69
Foreign exchange loss		—			605		—			—			605
Income (loss) before income taxes	$	2,238		$	1,486	$	(445	)	$	(5,917	)	$	(2,638	)

Depreciation and amortization included above	$	817		$	681	$	—		$	37		$	1,535

Share-based compensation included in above:
Selling, general and administrative		60		$	44		—		$	309			413
Total	$	60		$	44	$	—		$	309		$	413

Capital expenditures	$	994		$	72	$	—		$	—		$	1,066